Wei‐Lien Wang

The University of Texas MD Anderson Cancer Center — United States

Medicine · Health Sciences

55h-index13.0kcitations390works2.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(203), Vascular Tumors and Angiosarcomas(46), Bone Tumor Diagnosis and Treatments(45), Cardiac tumors and thrombi(42), Soft tissue tumor case studies(39)

Publications390 total

Supplementary Figures 1-2 from Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals <i>TP53</i> Mutation to Be Associated with Worse Outcomes
2025Open Access
Supplementary Tables 1-2 from Clinico-Genomic Profiling of Conventional and Dedifferentiated Chondrosarcomas Reveals <i>TP53</i> Mutation to Be Associated with Worse Outcomes
2025Open Access
Supplementary Table S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
2025Open Access
Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
2025Open Access
PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study
JCO oncology advances.·2025Open Access
Corrigendum to “Prognostic Model for Patient Survival in Primary Anorectal Mucosal Melanoma: Stage at Presentation Determines Relevance of Histopathologic Features” [Modern Pathology 33 (2020) 496–513]
Modern Pathology·2025
Real-world efficacy and safety of tarlatamab in patients with relapsed extensive-stage small cell lung cancer.
Journal of Clinical Oncology·2025· 2 cited
Building a pre-surgical multiparametric-MRI-based morphologic, qualitative, semiquantitative, first and high-order radiomic predictive treatment response model for undifferentiated pleomorphic sarcoma to replace RECIST
Cancer Imaging·2025· 4 citedOpen Access
Supplementary Table S3 from CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation
2025Open Access
Supplementary Table S4 from CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation
2025Open Access
Supplementary Table S2 from CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation
2025Open Access
Supplementary Table S1 from CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation
2025Open Access
Supplementary Table S5 from CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation
2025Open Access
Data from CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation
2025Open Access
Supplementary Figures 1 from CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation
2025Open Access
Supplementary Methods 1 from CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation
2025Open Access
72 Conventional Chondrosarcoma in the Pediatric Population, a Single-Institution Retrospective Review
Laboratory Investigation·2025
826 Primary Renal Sarcomas in Adult Patients: A Clinicopathologic Study of 62 Cases
Laboratory Investigation·2025Open Access
CA-125 as a Biomarker in Renal Medullary Carcinoma: Integrated Molecular Profiling, Functional Characterization, and Prospective Clinical Validation
Clinical Cancer Research·2025· 4 citedOpen Access
Novel Use and Value of Contrast-Enhanced Susceptibility-Weighted Imaging Morphologic and Radiomic Features in Predicting Extremity Soft Tissue Undifferentiated Pleomorphic Sarcoma Treatment Response
JCO Clinical Cancer Informatics·2025· 3 cited
page 1 of 20Next →

Frequent Co-authors

Alexander J. Lazar(37), Christina L. Roland(9), Dolores López‐Terrada(9), Jason L. Hornick(8), Davis R. Ingram(8), Robert S. Benjamin(7), Keila E. Torres(7), Dejka M. Araujo(6), Dina Lev(6), Shreyaskumar Patel(6), Anthony P. Conley(6), Víctor G. Prieto(6), Emily Z. Keung(5), Elizabeth G. Demicco(5), P. Andrew Futreal(5), Neeta Somaiah(5), Vinod Ravi(5), Angshumoy Roy(4), Jonathan C. Trent(4), Brian P. Rubin(4)